Denali Therapeutics Inc. (NASDAQ:DNLI) revealed topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS ...
A renowned Israeli TV journalist who lost his ability to speak clearly because of ALS is returning to the air using ...
Central Nervous System Disorders is under clinical development by Neuroplast and currently in Phase I for Amyotrophic Lateral Sclerosis.
Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...
Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...
Announcing a new publication for Acta Materia Medica journal. Complex biological mechanisms and unidentified therapeutic targets for amyotrophic lateral sclerosis (ALS) significantly hinder the develo ...
EST Denali falls 9% to $18 afteramyotrophic lateral sclerosis study missDon't Miss Our New Year's Offers:Discover the latest stocks ...
Amyotrophic lateral sclerosis (ALS) is a serious and usually fatal neurodegenerative disorder in which motor neurons deteriorate and die. | Genetics And Genomics ...
Thanks to awareness-raising initiatives like the Ice Bucket Challenge, we all have a better appreciation of amyotrophic ...
Neurosense entered a binding term sheet with a global pharmaceutical company to advance development and commercialization of ...